David Fischel has served as CEO and Chairman of the Board of Stereotaxis since February 2017 after previously serving as Director, having orchestrated the equity investment and positive strategic initiatives announced in September 2016. He previously served as Principal and portfolio manager for medical device investments at DAFNA Capital Management, LLC for over eight years. In addition to his research responsibilities, David has been deeply involved in all aspects of the firm’s operations including legal, accounting, IT, compliance, human resources and marketing. Prior to joining DAFNA Capital, he was a research analyst at SCP Vitalife, a healthcare venture capital fund. David completed his B.S. magna cum laude in Applied Mathematics with a minor in Accounting at the University of California at Los Angeles and received his MBA from Bar-Ilan University in Tel Aviv.
The MedTech giants remain indispensable in driving large-scale adoption and validating the market, but the smaller players are increasingly showing us what the future of robotics care can look like.
Robotics has already revolutionized fields like orthopedics and laparoscopic surgery. Endovascular care deserves the same leap forward. The technology exists. The evidence is strong. The challenge now is adoption.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases